Innocan Pharma closes non-brokered private placement

1 minute read
14 March 2024

On March 14, 2024, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced that it had closed its previously announced non-brokered private placement offering of units of the company for aggregate gross proceeds of $1,988,210. 

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. 

Gowling WLG advised Innocan with respect to this private placement with a team that included Jason A. Saltzman and Josh Rosen, assisted by student-at-law Derek Varrin.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.